The Namibia Population-based HIV Impact Assessment (NAMPHIA) 2017 | The Ministry of Health and Services is leading the NAMPHIA survey in collaboration with the Namibia Statistics Agency (NSA) and the Namibia Institute of Pathology (NIP). The survey is supported by the United States President’s Eme...rgency Plan for AIDS Relief (PEPFAR), through the U.S. Centers for Disease Control and Prevention (CDC). | The goal of NAMPHIA is to examine the current distribution of the HIV epidemic and assess the impact of Namibia’s prevention, care and treatment response across all 14 regions of Namibia.
more
An introduction to 90-90-90 in South Africa
O presente Guião de Bolso referente ao Tratamento antiretroviral e de infecções oportunistas
do adulto, adolescente e criança é um instrumento de grande utilidade para os profissionais de saúde, em especial os envolvidos no tratamento dos pacientes infectados pelo HIV em Moçambique. O Guião... salvaguarda uma abordagem correcta, atempada e padronizada no atendimento aos pacientes com HIV/SIDA, garantindo o uso racional e cientificamente fundamentado dos escassos recursos existentes.
more
Capability and Performance
Cerebrum. 2016 Jul-Aug; 2016: cer-10-16.
Published online 2016 Jul 1.
BMJ Glob Health 2019;4:e001272. doi:10.1136/bmjgh-2018-001272
Trust is an essential component of successful cooperative endeavours. The global health response to the 2014–2016 West Africa Ebola outbreak confronted historically tenuous regional relationships of trust. Challenging sociopolitical co...ntexts and initially inappropriate communication strategies impeded trustworthy relationships between communities and responders during the epidemic. Social scientists affiliated with the Ebola 100-Institut Pasteur project interviewed approximately 160 local, national and international responders holding a wide variety of roles during the epidemic
more
Bull World Health Organ 2016;94:554–556 | doi: http://dx.doi.org/10.2471/BLT.15.162610
The design of anaesthesia equipment for use in hospitals in the developing world must take intoaccount the local conditions, particularly whether reliable supplies of compressed oxygen andelectricity are available. Designs should ensure that maintenance is feasible locally. Internationalstandards sh...ould encourage the design of suitable equipment to ensure safe anaesthesia for patientsworldwide
Anaesthesia, 2007,62(Suppl. 1), pages 54–60
more
Les programmes de planification familiale sont une solution gagnant-gagnant ; le bien-être de chaque femme et des enfants est amélioré, et l'économie nationale et l'environnement en tirentles bénéfices
BMJ Global Health2019;4:e001504. doi:10.1136/bmjgh-2019-00150
The Lancet Global Health Volume 7, ISSUE 7, e912-e922, July 01, 2019
After 100 years of chemotherapy with impractical and toxic drugs, an oral cure for human African trypanosomiasis (HAT) is available: Fexinidazole. In this case, we review the history of drug discovery for HAT with special emphasis on the discovery, pre-clinical development, and operational challenge...s of the clinical trials of fexinidazole. The screening of the Drugs for Neglected Diseases initiative (DNDi) HAT-library by the Swiss TPH had singled out fexinidazole, originally developed by Hoechst (now Sanofi), as the most promising of a series of over 800 nitroimidazoles and related molecules. In cell culture, fexinidazole has an IC50 of around 1 µM against Trypanosoma brucei and is more than 100-fold less toxic to mammalian cells. In the mouse model, fexinidazole cures both the first, haemolymphatic, and the second, meningoencephalitic stage of the infection, the latter at 100 mg/kg twice daily for 5 days. In patients, the clinical trials managed by DNDi and supported by Swiss TPH mainly conducted in the Democratic Republic of the Congo demonstrated that oral fexinidazole is safe and effective for use against first- and early second-stage sleeping sickness. Based on the positive opinion issued by the European Medicines Agency in 2018, the WHO has released new interim guidelines for the treatment of HAT including fexinidazole as the new therapy for first-stage and non-severe second-stage sleeping sickness caused by Trypanosoma brucei gambiense (gHAT). This greatly facilitates the diagnosis and treatment algorithm for gHAT, increasing the attainable coverage and paving the way towards the envisaged goal of zero transmission by 2030.
more